Sanofi (GB:0O59)
LSE:0O59
0O59 Stock Chart & Stats
€82.83
€0.15(0.16%)
At close: 4:00 PM EST
€82.83
€0.15(0.16%)
Day’s Range― - ―
52-Week Range€70.92 - €98.36
Previous CloseN/A
Volume934.71K
Average Volume (3M)973.85K
Market Cap
€97.36B
Enterprise Value€111.43B
Total Cash (Recent Filing)€7.66B
Total Debt (Recent Filing)€21.80B
Price to Earnings (P/E)12.9
Beta0.76
Next Earnings
Apr 23, 2026EPS Estimate
1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.53
Shares Outstanding1,212,182,500
10 Day Avg. Volume1,112,792
30 Day Avg. Volume973,851
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.41
Price to Sales (P/S)2.31
P/FCF Ratio11.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€93.54Price Target Upside12.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)8.48
Revenue Forecast (FY)€48.18B
Bulls Say, Bears Say
Bulls Say
Key Product MomentumOngoing uptake of the flagship biologic Dupixent, supported by effective lifecycle management and faster adoption of biologic treatments in eczema, can sustain and grow core revenue.
Mergers & AcquisitionsStrong balance sheet and management focus on biomarker-driven cardiovascular, ophthalmology and oral immunology assets create capacity to pursue strategic acquisitions that could add new revenue streams.
Pipeline AdvancementMultiple late-stage studies and planned regulatory filings present clear pathways for future approvals that could materially expand the product portfolio if clinical and regulatory outcomes are favorable.
Bears Say
Amlitelimab Approval RiskLate-stage amlitelimab data missing original efficacy targets and showing weaker benefit than earlier results leaves approval prospects uncertain and poses a major downside risk to the investment case.
Management Transition RiskAppointment of a new chief executive creates uncertainty about future research priorities and business-development strategy, which could slow decision making and alter expected pipeline advancement.
Near-term Catalyst DroughtA light schedule of near-term development milestones combined with mixed clinical readouts and recent regulatory setbacks reduces immediate investor conviction and reliance on longer-term outcomes.
Sanofi News
0O59 FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest share price was €70.92 and its highest was €98.36 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is €97.36B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Apr 23, 2026 which is in 14 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jan 29, 2026. The company reported €1.53 earnings per share for the quarter, beating the consensus estimate of €1.448 by €0.082.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi does not currently pay dividends.
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.78.
How many shares outstanding does Sanofi have?
Sanofi has 1,212,182,500 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €1.53 in its last earnings report, beating expectations of €1.448. Following the earnings report the stock price went down -2.17%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in GB:0O59
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
0O59 Company Deck
0O59 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong financial and commercial execution in 2025, with robust top-line growth, margin expansion, cash generation, multiple high-impact product launches, and extensive pipeline progress and regulatory approvals. Notable challenges include a Phase III failure (tolebrutinib for PPMS), a safety signal (single Kaposi sarcoma case) requiring monitoring, reductions in Regeneron R&D reimbursement with medium-term BOI implications, and uncertainty in the vaccine market driven by recent U.S. schedule changes. On balance, the company’s positive financial results, successful launches, active BD/investment strategy, and constructive pipeline readouts outweigh the material but manageable challenges.View all GB:0O59 earnings summaries0O59 Stock 12 Month Forecast
Average Price Target
€93.54
▲(12.93% Upside)
Technical Analysis
Options Prices
Currently, No data available
---